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Abstract. The paper presents a simple synthesis of a series of new quinazolinone derivatives 
13a-i. First, the reaction of 5-hydroxyanthranilic acid (11) with acetic anhydride at 160–180oC 
for 2 h gave the intermediate 12 in high yield. This intermediate was then reacted with amines in 
acetic acid at 180 
o
C for 14 h to afford new quinazolinone derivatives 13a-i in 69–92%. 
Synthesized compounds were structurally confirmed using spectroscopic methods: 
1
H, 
13
CNMR 
and MS spectra. The bioassay result using three cancer cell lines including SKLU-1 (lung 
cancer), MCF-7 (breast cancer) and HepG-2 (liver cancer) showed that only compound 13e 
exhibited significant cytotoxic effect against cancer cell lines tested with IC50 values of 9.48, 
20.39 and 18.04 µg/ mL, respectively.  
Keywords: 6-Hydroxy-4(3H) quinazolinone, cytotoxic, cancer. 
Classification numbers: 1.2.4.   
1. INTRODUCTION 
Nowadays, one of the most important health-related problems in the developed and the 
developing countries is cancer. It is estimated that 9.6 million deaths occur in 2018 due to this 
disease. Globally, about 1 in 6 deaths is due to cancer. Additionally, statistics reported by the 
International Union Against Cancer (UICC) indicated that every year, more than 11 million new 
cases of cancer are diagnosed, among them more than 7 million people die of which maximum 
percentage is from low and middle-income countries [1]. One of the main reasons for this could 
be the drug resistance and adverse side effects of the chemotherapy [2]. In order to develop more 
effective and reliable anticancer agents that overcome these limitations, the search for novel 
antitumor agents is now urgent. 
Over the past few years, there has been an increasing interest in the development and 
pharmacology of heteroaromatic organic compounds in which quinazolinone forms an important 
class of pharmacophores in medicinal chemistry due to their potential in H bonding and π–π 
stacking interactions with aromatic amino acid residues of receptors [3-6]. Therefore, a number 
of drug molecules and biologically active compounds often contain quinazolinone frames. In 
addition, the quinazolinone frames are common scaffolds found in many diverse biological 
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compounds, e.g. luotonin A (1), rutaecarpine (2), tryptanthrin (3), chloroqualone (4), and 
alloqualone (5) (Fig. 1) [7, 8].  
 
 
Figure 1. Some alkaloids containing quinazolinone moiety. 
Indeed, several quinazolinone derivatives (6-10) (Fig. 2) have been reported to exhibit 
various types of pharmacological activities, including anticancer [9], antioxidant [10], antiviral 
[11], anticonvulsant [12], anti-inflammatory [13], antitubercular [14], anti-HIV [15], and so on. 
Furthermore, quinazolinone and their derivatives have been found to display several benefits 
over the agents that are clinically used [16] and closely connected to the anti-cancer therapies 
[17, 18]. Some quinazolinone derivatives (6-10) (Fig. 2) were proved substantial in treating 
human leukemia than the conventional agents, and showed the significant effect of 
quinazolinones derivatives against breast cancer cell lines [19-22]. 
 
 
 
Figure 2. Several reported quinazolinone derivatives as anticancer agents. 
Accordingly, in our continuous program for the search of novel anti-cancer agents, we 
continue to focus on the synthesis of new quinazolinone derivatives, and evaluate the cytotoxic 
effects on some cancer cell lines. The paper presents the result of this study.   
2. MATERIALS AND METHODS 
Chemistry: All products were examined by thin-layer chromatography (TLC), performed 
on Whatman® 250 μm Silica Gel GF Uniplates and visualized under UV light at 254 nm. 
Melting points were determined in open capillaries on Electrothermal IA 9200 Shimadzu 
apparatus and uncorrected. Purification was done by crystallization and the open flash silica gel 
column chromatography using Merck silica gel 60 (240 to 400 mesh). Nuclear magnetic 
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resonance spectra (
1
H and 
13
C NMR) were recorded using tetramethylsilane (TMS) as an internal 
standard on a Bruker 500 MHz spectrometer with CD3OD, CDCl3 and DMSO-d6 as solvents. 
Chemical shifts are reported in parts per million (ppm) downfield from TMS as internal 
standard, and coupling constants (J) are expressed in hertz (Hz). Multiplicities are shown as the 
abbreviations: s (singlet), brs (broad singlet), d (doublet), t (triplet), m (multiplet). Reagents and 
solvents were purchased from Aldrich or Fluka Chemical Corp. (Milwaukee, WI, USA) or 
Merck unless noted otherwise. Solvents were distilled and dried before use. 
Bioassay: All media, sera and other reagents used for cell culture were obtained from a 
GIBCO Co. Ltd. (Grand Island, New York, USA) and three human cancer cell lines for testing 
including HepG-2 (liver cancer), MCF-7 (breast cancer), and SKLU-1 (lung cancer) were 
provided by Institute of Biotechnology, Vietnam Academy of Science and Technology. The 
cytotoxic effect of the synthesized compounds was determined by a method of the American 
National Cancer Institute (NCI) as described in literature. Briefly, these cancer cell lines were 
grown as monolayers in 2 mM of L-glutamine, 10 mM of HEPES, 1.0 mM of sodium pyruvate, 
and supplemented with 10 % fetal bovine serum – FBS (GIBCO). Cells were cultured for 3–5 
days after the transfer, and maintained at 37 
o
C in a humidified atmosphere containing 5 % CO2. 
Assay samples were initially dissolved in DMSO and serially diluted to appropriate 
concentrations with a culture medium right before the assay. Then the cells in each well, 
incubated for 24 hours as described above, were treated with 20 µL of samples at 20 µg/mL; 4 
µg/mL; 0.8 µg/mL; 0.16 µg/mL. The plates were further incubated for 48 h. The medium was 
removed and the cells were fixed by 10 % solution of trifluoroacetic acid. The fixed cells were 
stained for 30 minutes by a staining solution (MTT). Protein-bound dye was dissolved in a 10 
mM tris-base solution and the ODs were measured at 510 nm using an Elisa reader. The IC50 
values were then calculated using Probits method. Ellipticin (Sigma) was used as a positive 
control and the values reported for the compounds are presented as averages of three 
determinations. 
Synthesis of 6-hydroxy-2methyl-4H-benzo[d][1,3]oxazin-4-one (12) 
A mixture of 5-hydroxy anthranilic acid (11) (5.0 g, 32.67 mmol) in acetic anhydride (15 
ml) was refluxed at 150 
o
C for 2 h. The mixture was then poured in ice-water. The resulting 
precipitates were filtered, washed with distilled water and dried in vacuum to afford 12 (5.03 g, 
87 %) which was used for next step. 
General procedure for the synthesis of 13a-i 
A mixture of 12 (1.0 g, 5.64 mmol) and primary amines (3 eq) in acetic acid (10 mL) was 
refluxed at 120 
o
C for 14 h. The reaction was monitored by TLC (n-hexane : ethyl acetate = 1 : 
1). The reaction mixture was then neutralized with 50 % NaHCO3 to pH = 7, and extracted with 
CH2Cl2 (3 × 20 mL). The organic phase was separated, dried on anhydrous Na2SO4 and 
evaporated in reduced vacuum to obtain the corresponding residues which was subjected to 
column chromatography on silica gel using n-hexane/ethyl acetate as eluting systems to give 
desired 13a-i.  
3-Ethyl-6-hydroxy-2-methylquinazolin-4(3H)-one (13a) 
White solid; Yield: 85 %; Mp: 224-225 
o
C; Rf = 0.51
 
(n-hexane : ethyl acetate = 1 : 1);
  1
H 
NMR (500 MHz, CD3OD, δ (ppm)): 7.50-7.48 (overlap, 2H, H-5, H-8), 7.29 (dd, J = 3.0 Hz, 9.0 
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Hz, H-7), 2.66 (s, 3H, CH3), 4.22 (q, J = 7.50 Hz, 2H, H-1´), 1.36 (t, J = 7.0 Hz, 3H, CH3, H-2´). 
13
C NMR (125 MHz, CD3OD, δ (ppm)): 163.3 (C-4), 157.7 (C-6), 153.6 (C-2), 141.80 (C-9), 
128.6 (C-8), 125.3 (C-7), 122.4 (C-10), 110.2 (C-5), 40.8 (C-1´), 22.6 (CH3), 13.8 (C-2´). ESI-
MS m/z: 205.3 [M+H]
+
. 
 6-Hydroxy-2-methyl-3-propylquinazolin-4(3H)-one (13b)  
White solid; Yield: 91%; Mp: 260-261
o
C; Rf = 0.53
 
(n-hexane : ethyl acetate = 1 : 1);
  1
H 
NMR (500 MHz, DMSO-d6, δ (ppm)): 9.96 (s, 1H, OH), 7.44 (d, J = 8.50 Hz, 1H, H-8), 7.38 (d, 
J = 2.50 Hz, 1H, H-5), 7.22 (dd, J = 2.50 Hz, 8.50 Hz, 1H, H-7), 3.95 (t, J = 6.50 Hz, 2H, H-1´), 
2.54 (s, 3H, CH3), 1.66-1.62 (m, 2H, H-2´), 0.92 (t, J = 7.50 Hz, 3H, CH3, H-3´). 
13
C NMR (125 
MHz, DMSO-d6, δ (ppm)): 160.9 (C-4), 155.6 (C-6), 151.4 (C-2), 140.4 (C-9), 128.1 (C-8), 
123.7 (C-7), 120.9 (C-10), 108.8 (C-5), 45.3 (C-1´), 22.4 (CH3), 21.3 (C-2´), 11.1 (C-3´). ESI-
MS m/z: 219.5 [M+H]
+
. 
3-Butyl-6-hydroxy-2-methylquinazolin-4(3H)-one (13c)  
Bright yellow solid; Yield: 92 %; Mp: 140-141 
o
C; Rf = 0.57
 
(n-hexane : ethyl acetate = 1 : 
1);
 1
H NMR (500 MHz, CDCl3, δ (ppm)): 7.85 (d, J = 3.0 Hz, H-5), 7.54 (d, J = 9.0 Hz, H-8), 
7.31 (dd, J = 3.0 Hz, 9,0 Hz, 1H, H-7), 7.63 (brs, 1H, OH), 4.09 (t, J = 3.0 Hz, 2H, H-1´), 2.64 
(s, 3H, CH3), 1.74-1.70 (m, 2H, H-2´), 1.50-1.46 (m, 2H, H-3´), 1.0 (t, J = 2.5 Hz, 3H, CH3, H-
4´). 13C NMR (125 MHz, CDCl3, δ (ppm)): 162.2 (C-4), 155.2 (C-6), 152.4 (C-2), 141.4 (C-9), 
128.3 (C-8), 124.2 (C-7), 121.2 (C-10), 110.1 (C-5), 44.7 (C-1´), 30.7 (C-2´), 22.8 (CH3), 20.3 
(C-3´), 13,7 (C-4´). ESI-MS m/z: 233.3 [M+H]+. 
3-(sec-Butyl)-6-hydroxy-2-methylquinazolin-4(3H)-one (13d). Oil; Yield: 88 %;  Rf = 0.57
 
(n-
hexane : ethyl acetate = 1 : 1);
   1
H NMR (500 MHz, CD3OD, δ (ppm)): 7.49 (d, J = 8.50 Hz, 1H, 
H-8), 7.46 (d, J = 3.0 Hz, 1H, H-5), 7.28 (dd, J = 3.0 Hz, 8.50 Hz, 1H, H-7), 3.79 (m, 1H, H-1´), 
1.94 (s, 3H, CH3), 1.47 (m, 2H, H-2´), 1.12 (d, J = 6.50 Hz, 3H, CH3, H-5´), 0.91 (t, J = 7.50 Hz, 
3H, CH3, H-4´). 
13
C NMR (125 MHz, CD3OD, δ (ppm)): 172.5 (C-4), 157.7 (C-6), 154.2 (C-2), 
141.5 (C-9), 128.4 (C-8), 125.2 (C-7), 109.9 (C-10), 54.8 (C-1´), 23.9 (CH3), 22.6 (C-2´), 20.4 
(C-4´), 10.8 (C-3´). ESI-MS m/z: 233.3 [M+H]+. 
3-Benzyl-6-hydroxy-2-methylquinazolin-4(3H)-one (13e) 
White solid; Yield: 79 %; Mp: 64-65 
o
C; Rf = 0.50
 
(n-hexane : ethyl acetate = 1 : 1);
 1
H 
NMR (500 MHz, DMSO, δ (ppm)): 8.31 (brs, 1H, OH), 7.50 (d, J = 9.0 Hz, 1H, H-8), 7.45 (d, J 
= 3.0 Hz, 1H, H-5), 7.36-7.28 (m, 3H, H-7, H-4´, H-6´), 7.26-7.21 (m, 2H, H-3´, H-7´), 7.17 (d, 
J = 7.50 Hz, 1H, H-5´), 5.35 (s, 2H, H-1´), 1.87 (s, 3H, CH3). 
13
C NMR (125 MHz, DMSO-d6, δ 
(ppm)): 169.2 (C-4), 161.3 (C-6), 155.9 (C-2), 139.6 (C-9), 136.7 (C-2´), 128.8 (C-8), 128.3 (C-
4´, C-6´), 127.2 (C-5´), 126.7 (C-7), 126.2 (C-10), 109.1 (C-5), 46.3 (C-1´), 22.5 (CH3). ESI-MS 
m/z: 267.2 [M+H]
+
. 
6-Hydroxy-2-methyl-3-(4-methylbenzyl)quinazolin-4(3H)-one (13f)  
White solid; Yield: 69 %; Mp: 246-247 
o
C; Rf = 0.55
 
(n-hexane : ethyl acetate = 1 : 1);
 1
H 
NMR (500 MHz, DMSO-d6, δ (ppm)): 10.05 (s, 1H, OH), 7.49 (d, J = 8.80 Hz, 1H, H-8), 7.43 
(d, J = 2.80 Hz, 1H, H-5), 7.28 (dd, J = 3.20 Hz, 8.80 Hz, 1H, H-7), 7.15 (d, J = 8.80 Hz, 2H, H-
4´, H-6´), 7.04 (d, J = 8.80 Hz, 2H, H-3´, H-7´), 5.30 (s, 2H, H-1´), 2.42 (s, 3H, CH3), 2.08 (s, 
3H, CH3). 
13
C NMR (125 MHz, DMSO-d6, δ (ppm)): 169.5 (C-4), 161.8 (C-6), 156.4 (C-2), 
152.1 (C-9), 140.9 (C-5´), 134.1 (C-2´), 129.8 (C-8), 128.8 (C-4´, C-6´), 128.2 (C-3´, C-7´), 
124.6 (C-2´), 121.3 (C-7, C-10), 109.6 (C-5), 46.5 (C-1´), 23.1 (CH3), 21.2 (CH3). ESI-MS m/z: 
281.5 [M+H]
+
. 
6-Hydroxy-3-(4-methoxybenzyl)-2-methylquinazolin-4(3H)-one (13g)  
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White solid; Yield: 79 %; Rf = 0.49
 
(n-hexane : ethyl acetate = 1 : 1);
 1
H NMR (500 MHz, 
DMSO-d6, δ (ppm)): 10.03 (s, 1H, OH), 7.48 (d, J = 8.50 Hz, 1H, H-8), 7.44 (d, J = 2.50 Hz, 
1H, H-5), 7.26 (dd, J = 2.50 Hz, 8.50 Hz, 1H, H-7), 7.13 (d, J = 8.50 Hz, 2H, H-3´, H-7´), 6.90 
(d, J = 8.50 Hz, 2H, H-4´, H-6´), 5.27(s, 2H, H-1´), 3.71 (s, 3H, OCH3), 2.44 (s, 3H, CH3). 
13
C 
NMR (125 MHz, DMSO-d6, δ (ppm)): 161.3 (C-4), 158.4 (C-5´), 155.8 (C-6´), 151.6 (C-2), 
140.4 (C-9), 128.6 (C-3´, C-7´), 128.2 (C-2´), 127.8 (C-8), 123.9 (C-7), 120.8 (C-10), 114.1 (C-
4´, C-6´), 109.1 (C-5), 55.0 (OCH3), 45.7 (C-1´), 22.6 (CH3). ESI-MS m/z: 297.2 [M+H]
+
. 
3-(4-Fluorobenzyl)-6-hydroxy-2-methylquinazolin-4(3H)-one (13h)  
White solid; Yield: 81 %; Mp: 96-97 
o
C; Rf = 0.52
 
(n-hexane : ethyl acetate = 1 : 1);
 1
H 
NMR (500 MHz, DMSO-d6, δ (ppm)): 10.04 (s, 1H, OH), 7.49 (d, J = 9.0 Hz, 1H, H-8), 7.43 (d, 
J = 3.0 Hz, 1H, H-5), 7.28-7.25 (dd, J = 3.0 Hz, 9.0 Hz, 1H, H-7), 7.24-7.22 (d, J = 8.50 Hz, 2H, 
H-3´, H-7´), 7.18-7.16 (d, J = 8.50 Hz, 2H, H-4´, H-6´), 5.32 (s, 2H, H-1´), 2.50 (s, 3H, CH3); 
13
C NMR (125 MHz, DMSO-d6, δ (ppm)): 162.3 (C-4), 161.3 (C-5´), 160.3 (C-6), 155.9 (C-2), 
140.4 (C-9), 132.9 (C-2´), 128.5 (C-8), 128.4 (C-3´, C-7´), 128.3 (C-7), 124.9 (C-10), 115.6 (C-
4´, C-6´), 109.1 (C-5), 45.7(C-1´), 22.6 (CH3). ESI-MS m/z: 285.2 [M+H]
+
. 
 3-(4-Chlorobenzyl)-6-hydroxy-2-methylquinazolin-4(3H)-one (13i)  
White solid; Yield: 82 %; Mp: 113-114 
o
C; Rf = 0.53
 
(n-hexane : ethyl acetate = 1 : 1);
 1
H 
NMR (500 MHz, DMSO-d6, δ (ppm)): 10.07 (s, 1H, OH), 7.49 (d, J = 9.0 Hz, 1H, H-8), 7.43 (d, 
J = 3.0 Hz, 1H, H-5), 7.04-7.38 (d, J = 8.50 Hz, 2H, H-3´, H-7´), 7.28 (dd, J = 3.0 Hz, 9.0 Hz, 
1H, H-7), 7.21 (d, J = 8.50 Hz, 2H, H-4´, H-6´), 5.33 (s, 2H, H-1´), 2.42 (s, 3H, CH3). 
13
C NMR 
(125 MHz, DMSO-d6, δ (ppm)): 161.3 (C-4), 155.9 (C-6), 151.4 (C-2), 140.4 (C-9), 135.7 (C-
5´), 131.8 (C-2´), 128.7 (C-3´, C-7´), 128.3 (C-8), 124.0 (C-4´, C-6´), 120.8 (C-7, C-10), 109.1 
(C-5), 45.8 (C-1´), 22.6 (CH3). ESI-MS m/z: 301.1 [M+H]
+
. 
3. RESULTS AND DISCUSSION 
3.1. Chemistry 
Novel quinazolinone derivatives 13a-i were synthesized as outlined in Scheme 1. 6-
hydroxyanthranilic acid (11) was first condensed with the excess of acetic anhydride at 160 
o
C 
for 2 h to afford the desired benzoxazinone 12 in 87 % yields. The purification of compound 12 
was simply carried out by pouring the reaction mixture into the ice-water. The resulting 
precipitates was filtered, washed with distilled water, and dried in vacuum. Compound 12 was 
next coupled to alkyl amines, benzylamines to give target compounds 13a–i in good to excellent 
yields. All the synthesized compounds were characterized by 
1
H NMR, 
13
C NMR and MS 
spectra. Due to the structural similarity of target compounds, compound 13h was used as an 
example to elucidate the structure of synthesized compounds. In the 
1
H NMR spectrum, the 
chemical shift at the lowest field at 10.04 ppm is attributed to OH group. The characteristic 
splitting pattern of 3 protons H-5, H-7 and H-8 as ABC system of quinazolinone skeleton was 
easily observed. The proton H-5 resonates as a doublet at 7.43 ppm (J = 3.0 Hz) resulting from 
long coupling with H-7. The proton H-8 resonates as a doublet at δ 7.49 (J = 9.0 Hz) due to near 
coupling with H-7. The proton H-7 was observed as a doublet of doublet at δ 7.26 (d, J = 3.0 Hz, 
9.0 Hz) due to coupling with H-8 and H-7. Besides, four protons of aromatic ring were observed 
as two doublets at 7.24-7.22 ppm (J = 8.50 Hz, 2H, H-3´, H-7´), and 7.18-7.16 ppm (d, J = 8.50 
Hz, 2H, H-4´, H-6´), and the strong singlet signal at 5.32 ppm is assigned to CH2-benzyl. CH3 
group connecting to quinazolinone moiety resonates at 2.50 ppm. The 
13
C NMR spectrum 
showed the presence of 14 carbons in the molecule, in which the carbonyl signal was observed at 
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δ 162.3 ppm. The signal at δ 161.3 ppm is attributed to C-5´ due to connecting to F and signal at 
155.9 ppm belongs to C-2. In addition, two couples of four equivalent carbons resonate at δ 
127.8 and 115.6 ppm. 
 
 
Scheme 1. Reagents and conditions: (i) (CH3CO)2O, 160–180 
o
C, 2 h; (ii) acetic acid, amines,                              
180 
o
C, 14 h, 69–92 %. 
Table 1. In vitro cytotoxic activity of quinazolinone derivatives 13a-i. 
No Compounds R IC50 (µg/mL) 
SK-LU-1 MCF-7 HepG-2 
1 13a Ethyl >100 >100 >100 
2 13b n-Propyl >100 >100 >100 
3 13c n-Butyl >100 >100 >100 
4 13d sec-Butyl >100 >100 >100 
5 13e Benzyl 9.48 20.39 18.04 
6 13f 4-Methylbenzyl >100 >100 >100 
7 13g 4-
Methoxybenzyl 
>100 >100 >100 
8 13h 4-Fluorobenzyl >100 >100 >100 
9 13i 4-Chlorobenzyl >100 >100 >100 
 Ellipticine  0.43 0.43 0.40 
a
Concentration (µg/mL) that produces a 50 % reduction in cell growth or enzyme activity, the numbers 
represent the averaged results from triplicate experiments with deviation of less than 10 %. 
b
Cell lines: 
HepG2, liver cancer; MCF-7, breast cancer; SKLU-1, lung cancer. 
 
All target compounds 13a-i were evaluated for their in vitro cytotoxicity. Three human 
cancer cell lines including SKLU-1, MCF-7 and HepG-2 were chosen for screening their 
inhibition effect using MTT method [23]. All compounds were initially screened at a fixed 
concentration of 100 µg/mL. If the compounds are active, they will be further screened at 
smaller concentrations (e.g., 20 µg/mL, 4 µg/mL, 0.8 µg/mL and 0.16 µg/mL), and IC50 values 
for each compound were calculated (Table 1). In this assay, ellipticine was used as a positive 
control. 
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However, as shown in Table 1, most of quiniazolinone derivatives were inactive against 
three cancer cell lines tested except compound 13e showing cytotoxic effect with IC50 values of 
9.48, 20.39 and 18.04 µg/mL, respectively. 
4. CONCLUSIONS 
We have reported a series of new quinazolinone derivatives 13a-i via a simple synthetic 
procedure. The structure of all synthesized compounds has been confirmed based on 
1
H, 
13
C 
NMR and MS spectra. Although the bioassay results showed that most of target compounds 
exhibited no cytotoxic effect in terms of cytotoxicity in comparison with ellipticine, compound 
13e displayed cytotoxic effect with IC50 values of 9.48, 20.39 and 18.04 µg/mL, respectively, 
suggesting that it could be served as basis for further design of antitumor agents in the future.  
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